Zhongguo ying yong sheng li xue za zhi, 2016-06, Vol.32 (6), p.525
2016
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- The efficacy of TKIs in treatment of human primary small cell lung cancer xenograft model in vivo
- Ist Teil von
- Zhongguo ying yong sheng li xue za zhi, 2016-06, Vol.32 (6), p.525
- Ort / Verlag
- China
- Erscheinungsjahr
- 2016
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- To study the treatmaient of non-small cell lung cancer, we established the HU-Prim allograft transplantation tumor model. The fresh tumor samples were transplanted in the right scapular subcutaneous layer of the severe combined immunodeficient Non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice. The pathological features of the tumors were observed. Nonnecrotic tissue was inoculated subcutaneously into the right axillary. When the tumor in burdened rat grew approximately 100 mm , according to the tumor size all the animals were divided into the following four groups, eight rats in each group:solvent control group, gefitinib group (100 mg/kg), erlotinib group (50 mg/kg), afatinib group (20 mg/kg). Aniamals were treated with drugs by intragastric (i.g.) administrated, once daily, for consecutively 14 days. Measure the tumor size 2-3 times every week. HuPrime1-NSCLC mutant sensitive xenograft model research data showed that reversible tyrosine kinase inhibitors gefitinib, erlotinib and irreversibl
- Sprache
- Chinesisch
- Identifikatoren
- ISSN: 1000-6834DOI: 10.13459/j.cnki.cjap.2016.06.009Titel-ID: cdi_pubmed_primary_29926620
- Format
- –
- Schlagworte
- Afatinib, Animals, Antineoplastic Agents - pharmacology, Carcinoma, Non-Small-Cell Lung - drug therapy, Cell Line, Tumor, Erlotinib Hydrochloride - pharmacology, Gefitinib, Humans, Lung Neoplasms - drug therapy, Mice, Mice, Inbred NOD, Mice, SCID, Protein Kinase Inhibitors - pharmacology, Quinazolines - pharmacology, Xenograft Model Antitumor Assays